	RIDGEMONT EQUITY PARTNERS III, L.P., RIDGEMONT EQUITY	Total Fund			Ridgemont Equity Management III, L.P.			Teachers' Retirement System of the State of Illinois		
	PARTNERS AFFILIATES III, L.P., AND THEIR AFFILIATED ALTERNATIVE INVESTMENT VEHICLES ("AIVs")	Current Period	YTD	Since Inception	Current Period	YTD	Since Inception	Current Period	YTD	Since Inception
		(Jul 1, 2021 -	(Jan 1, 2021 -	(Jul 31, 2018 -	(Jul 1, 2021 -	(Jan 1, 2021 -	(Jul 31, 2018 -	(Jul 1, 2021 -	(Jan 1, 2021 -	(Jul 31, 2018 -
		Sep 30, 2021)	Sep 30, 2021)	Sep 30, 2021)	Sep 30, 2021)	Sep 30, 2021)	Sep 30, 2021)	Sep 30, 2021)	Sep 30, 2021)	Sep 30, 2021)
	Beginning Balance	\$ 1,412,382,358	\$ 1,036,837,657	\$ -	\$ 90,592,010	\$ 56,707,654	\$ -	\$ 43,944,480 \$	32,521,050	\$ -
	Contributions	4,020,245	2,801,608	1,046,070,937	1,500	1,045	54,644,183		_	32,788,532
	Distributions	4,020,243	2,001,000	1,040,070,537	1,500	1,043	54,044,105			32,700,332
	Distributions - Cash	-	(90,000,000)	(90,000,000)	545	(8,089,774)	(8,089,774)		(2,727,273)	(2,727,273)
	Distributions - Deemed (Federal & State Taxes) Distributions - Deemed (ECI)	(824,796)	(945,591)	(1,082,955)	4,098	(4,286)	(14,925)	2,059	(752)	(1,057)
	Distributions - Deemed (FDAP)	(101,822)	(101,869)	(101,869)		_	-		-	-
	Subtotal: Distributions	(926,618)	(91,047,460)	(91,184,824)	4,643	(8,094,060)	(8,104,699)	2,059	(2,728,025)	(2,728,330)
	Total Contributions & Distributions	3,093,627	(88,245,852)	954,886,113	6,143	(8,093,015)	46,539,484	2,059	(2,728,025)	30,060,202
	Equity Reduction for Placement Fees	-	-	(4,611,989)	-	-	(421,371)	-	-	(142,064)
	Net Operating Income									
	(Gross Management Fees)	(7,508,437)		(76,419,205)	-	-	-	(250,000)	(750,000)	(2,544,444)
	Management Fee Offset: Deemed Contribution	5,888,828	20,637,822	36,423,429	-	-	-	199,635	699,635	1,234,777
	Management Fee Offset: Organization Expenses Management Fee Offset: Placement Fees	7,704	7,704	36,885 4,190,618		-	-	261	261	1,250 142,065
	Management Fee Offset: Portfolio Company Fees	1,483,844	1,590,629	6,078,507	_	_	_	50,104	50,104	199,532
	(Line of Credit Interest Expense)	(288,720)		(9,110,970)	(26,379)	(65,220)	(832,417)	(8,894)	(21,989)	(280,648)
	(Organizational Expenses)	-	-	(2,134,555)	-	-	(182,744)	-	-	(61,596)
	(Operating Expenses) Interest Income	(1,294,724) 424	(3,326,568) 1,545	(10,598,297) 5,959	(110,236)	(289,634)	(934,553)	(37,174)	(97,871)	(315,223)
	Dividend Income	23,000,000	23,000,000	23,000,000	2,067,386	2,067,386	2,067,386	696,970	696,970	696,970
	Other Income	2,325,555	6,205,320	7,011,998	209,036	557,773	630,283	70,472	188,040	212,485
	Other Interest Earned	-	-	1,219,185	-	-	109,588	-	-	36,946
	Realized Gain/(Loss) Total Net Operating Income	23,614,474	24,877,299	(20,296,446)	2,139,807	2,270,305	857,544	721,374	765,150	- (677,886)
										1
	Unrealized Gain/(Loss)	184,245,052	649,866,407	693,357,833	16,561,120	58,414,136	62,323,423	5,583,183	19,692,921	21,010,844
	Ending NAV Potential Incentive Allocations	1,623,335,511	1,623,335,511	1,623,335,511	109,299,080 113,853,275	109,299,080 113,853,275	109,299,080 113,853,275	50,251,096 (3,791,223)	50,251,096 (3,791,223)	50,251,096 (3,791,223)
	Ending NAV After Potential Incentive Allocation	\$ 1,623,335,511	\$ 1,623,335,511	\$ 1,623,335,511		\$ 223,152,355		\$ 46,459,873 \$	46,459,873	
	Total Commitment			6 1 (50 000 000						
	Total Committee						\$ 148.312.518			\$ 50,000,000
				\$ 1,650,000,000			\$ 148,312,518			\$ 50,000,000
	Beginning Unfunded Commitment	\$ 655,332,011		\$ 1,650,000,000	\$ 59,142,857		\$ 148,312,518	\$ 19,938,741 \$	17,211,468	\$ 50,000,000
	Less: Contributions	\$ 655,332,011 (4,020,245)	(2,801,608)	1,650,000,000 (1,046,070,937)	\$ 59,142,857 (1,500)	(1,045)	\$ 148,312,518 (54,644,183)	\$ 19,938,741 \$ -	17,211,468	\$ 50,000,000 (32,788,532)
	Less: Contributions Plus: Recallable Distributions			\$ 1,650,000,000			\$ 148,312,518	\$ 19,938,741 \$ - -		\$ 50,000,000
	Less: Contributions		(2,801,608)	\$ 1,650,000,000 (1,046,070,937) 90,000,000 (6,193,867)		(1,045)	\$ 148,312,518 (54,644,183) 8,090,319 (6,193,867)	\$ 19,938,741 \$	17,211,468	\$ 50,000,000 (32,788,532)
	Less: Contributions Plus: Recallable Distributions Less: Reduction for No Self-Charged Management Fee to General Partner Less: Deemed Contribution		(2,801,608)	\$ 1,650,000,000 (1,046,070,937) 90,000,000		(1,045)	\$ 148,312,518 (54,644,183) 8,090,319	S 19,938,741 S	17,211,468	\$ 50,000,000 (32,788,532)
	Less: Contributions Plus: Recallable Distributions Less: Reduction for No Self-Charged Management Fee to General Partner		(2,801,608) 90,000,000	\$ 1,650,000,000 (1,046,070,937) 90,000,000 (6,193,867) (36,423,430)		(1,045) 8,090,319	\$ 148,312,518 (54,644,183) 8,090,319 (6,193,867) (36,423,430)	\$ 19,938,741 \$ 	17,211,468	\$ 50,000,000 (32,788,532) 2,727,273
	Less: Contributions Plus: Recallable Distributions Less: Reduction for No Self-Charged Management Fee to General Partner Less: Deemed Contribution Plus: Other Adjustment Ending Unfunded Commitment	(4,020,245) - - - - - - - - - - - - - - - - - - -	(2,801,608) 90,000,000	\$ 1,650,000,000 (1,046,070,937) 90,000,000 (6,193,867) (36,423,430)	(1,500)	(1,045) 8,090,319	\$ 148,312,518 (54,644,183) 8,090,319 (6,193,867) (36,423,430)	-	17,211,468 - 2,727,273	\$ 50,000,000 (32,788,532) 2,727,273
	Less: Contributions Plus: Recallable Distributions Less: Reduction for No Self-Charged Management Fee to General Partner Less: Deemed Contribution Plus: Other Adjustment Ending Unfunded Commitment Portfolio Company Remuneration ("PCR") Information (Monitoring and Closi	(4,020,245)	(2,801,608) 90,000,000 - - \$ 651,311,766	\$ 1,650,000,000 (1,046,070,937) 90,000,000 (6,193,867) (36,423,430) - \$ 651,311,766	(1,500)	(1,045) 8,090,319	\$ 148,312,518 (54,644,183) 8,090,319 (6,193,867) (36,423,430)	S 19,938,741 S	17,211,468 - 2,727,273 - - 19,938,741	\$ 50,000,000 (32,788,532) 2,727,273 - - - \$ 19,938,741
	Less: Contributions Plus: Recallable Distributions Less: Reduction for No Self-Charged Management Fee to General Partner Less: Deemed Contribution Plus: Other Adjustment Ending Unfunded Commitment Portfolio Company Remuneration ("PCR") Information (Monitoring and Clost Total PCR Received by the Manager ("Total PCR")*	(4,020,245)	(2,801,608) 90,000,000 - - - \$ 651,311,766	\$ 1,650,000,000 (1,046,070,937) 90,000,000 (6,193,867) (36,423,430) \$ 651,311,766	(1,500)	(1,045) 8,090,319	\$ 148,312,518 (54,644,183) 8,090,319 (6,193,867) (36,423,430)	\$ 19,938,741 \$	17,211,468 2,727,273 - 19,938,741	\$ 50,000,000 (32,788,532) 2,727,273 - - - \$ 19,938,741
	Less: Contributions Plus: Recallable Distributions Less: Reduction for No Self-Charged Management Fee to General Partner Less: Deemed Contribution Plus: Other Adjustment Ending Unfunded Commitment Portfolio Company Remuneration ("PCR") Information (Monitoring and Closi	(4,020,245)	(2,801,608) 90,000,000 - - \$ 651,311,766	\$ 1,650,000,000 (1,046,070,937) 90,000,000 (6,193,867) (36,423,430) - \$ 651,311,766	(1,500)	(1,045) 8,090,319	\$ 148,312,518 (54,644,183) 8,090,319 (6,193,867) (36,423,430)	S 19,938,741 S	17,211,468 - 2,727,273 - - 19,938,741	\$ 50,000,000 (32,788,532) 2,727,273 - - - \$ 19,938,741
	Less: Contributions Plus: Recallable Distributions Less: Reduction for No Self-Charged Management Fee to General Partner Less: Deemed Contribution Plus: Other Adjustment Ending Unfunded Commitment Portfolio Company Remuneration ("PCR") Information (Monitoring and Closi Total PCR Received by the Manager ("Total PCR")* PCR Received by the Manager, Allocable to REP III* Percentage of Total PCR Allocable to REP III	(4,020,245)	(2,801,608) 90,000,000 - - - \$ 651,311,766 3,638,949 977,473 2,661,476 73.14%	\$ 1,650,000,000 (1,046,070,937) 90,000,000 (6,193,867) (36,423,430) \$ 651,311,766 19,425,036 6,090,789 13,334,247 68.64%	(1,500)	(1,045) 8,090,319	\$ 148,312,518 (54,644,183) 8,090,319 (6,193,867) (36,423,430)	\$ 19,938,741 \$ N/A N/A N/A N/A	17,211,468 2,727,273 - 19,938,741 N/A N/A N/A N/A	\$ 50,000,000 (32,788,532) 2,727,273 - - - \$ 19,938,741 N/A N/A N/A
	Less: Contributions Plus: Recallable Distributions Less: Reduction for No Self-Charged Management Fee to General Partner Less: Deemed Contribution Plus: Other Adjustment Ending Unfunded Commitment Portfolio Company Remuneration ("PCR") Information (Monitoring and Closi Total PCR Received by the Manager ("Total PCR")* PCR Received by the Manager, Allocable to Related Entities PCR Received by the Manager, Allocable to REP III PCR Received by the Manager, Allocable to REP III PCR Received by the Manager, Allocable to REP III	(4,020,245)	(2,801,608) 90,000,000 - - - S 651,311,766 3,638,949 977,473 2,661,476 73,149% 2,422,245	\$ 1,650,000,000 (1,046,070,937) 90,000,000 (6,193,867) (36,423,430) - \$ 651,311,766 19,425,036 6,090,789 13,334,247 68,649% 12,135,680	(1,500)	(1,045) 8,090,319	\$ 148,312,518 (54,644,183) 8,090,319 (6,193,867) (36,423,430)	\$ 19,938,741 \$ N/A N/A N/A N/A N/A S3,164	17,211,468 - 2,727,273 - 19,938,741 N/A N/A N/A N/A 80,651	\$ 50,000,000 (32,788,532) 2,727,273 - - \$ 19,938,741 N/A N/A N/A N/A N/A 404,068
	Less: Contributions Plus: Recallable Distributions Less: Reduction for No Self-Charged Management Fee to General Partner Less: Deemed Contribution Plus: Other Adjustment Ending Unfunded Commitment Portfolio Company Remuneration ("PCR") Information (Monitoring and Clos Total PCR Received by the Manager ("Total PCR")* PCR Received by the Manager, Allocable to Related Entities PCR Received by the Manager, Allocable to REP III PCR Received by the Manager, Allocable to REP III PCR Received by the Manager, Allocable to REP III PCR Received by the Manager, Allocable to REP III PCR Received by the Manager, Allocable to REP III PCR Received by the Manager, Allocable to REP III LPs Remaining PCR Offset Allocable to REP III LPs	(4,020,245) \$ 651,311,766 ng Fees): 2,139,672 385,257 1,754,414 81,99% 1,596,716 6,057,173	(2,801,608) 90,000,000 - - - S 651,311,766 3,638,949 977,473 2,661,476 73,14% 2,422,245 6,057,173	\$ 1,650,000,000 (1,046,070,937) 90,000,000 (6,193,867) (36,423,430) \$ 651,311,766 19,425,036 6,090,789 13,334,247 68,64% 12,135,680 6,057,173	(1,500)	(1,045) 8,090,319	\$ 148,312,518 (54,644,183) 8,090,319 (6,193,867) (36,423,430)	N/A N/A N/A N/A S3,164 204,536	17,211,468 - 2,727,273 - - - 19,938,741 N/A N/A N/A N/A N/A 20,651 204,536	\$ 50,000,000 (32,788,532) 2,727,273 - - \$ 19,938,741 N/A N/A N/A N/A N/A 404,068 204,536
	Less: Contributions Plus: Recallable Distributions Less: Reduction for No Self-Charged Management Fee to General Partner Less: Deemed Contribution Plus: Other Adjustment Ending Unfunded Commitment Portfolio Company Remuneration ("PCR") Information (Monitoring and Closi Total PCR Received by the Manager ("Total PCR")* PCR Received by the Manager, Allocable to Related Entities PCR Received by the Manager, Allocable to REP III PCR Received by the Manager, Allocable to REP III PCR Received by the Manager, Allocable to REP III	(4,020,245)	(2,801,608) 90,000,000 - - - S 651,311,766 3,638,949 977,473 2,661,476 73,149% 2,422,245	\$ 1,650,000,000 (1,046,070,937) 90,000,000 (6,193,867) (36,423,430) - \$ 651,311,766 19,425,036 6,090,789 13,334,247 68,649% 12,135,680	(1,500)	(1,045) 8,090,319	\$ 148,312,518 (54,644,183) 8,090,319 (6,193,867) (36,423,430)	\$ 19,938,741 \$ N/A N/A N/A N/A N/A S3,164	17,211,468 - 2,727,273 - 19,938,741 N/A N/A N/A N/A 80,651	\$ 50,000,000 (32,788,532) 2,727,273 - - \$ 19,938,741 N/A N/A N/A N/A N/A 404,068
	Less: Contributions Plus: Recallable Distributions Less: Reduction for No Self-Charged Management Fee to General Partner Less: Deemed Contribution Plus: Other Adjustment Ending Unfunded Commitment Portfolio Company Remuneration ("PCR") Information (Monitoring and Closi Total PCR Received by the Manager ("Total PCR")* PCR Received by the Manager, Allocable to Related Entities PCR Received by the Manager, Allocable to ReP III* Percentage of Total PCR Allocable to REP III LPs Remaining PCR Offiset Allocable to REP III LPs Remaining PCR Offiset Allocable to REP III LPs Remaining PCR Offiset Allocable to REP III LPs Percentage of PCR Allocable to REP III LPs Remaining PCR Offiset Allocable to REP III LPs Remaining PCR Offise	(4,020,245) \$ 651,311,766 ng Fees): 2,139,672 385,257 1,754,414 81,99% 1,596,716 6,057,173	(2,801,608) 90,000,000 - - - S 651,311,766 3,638,949 977,473 2,661,476 73,14% 2,422,245 6,057,173	\$ 1,650,000,000 (1,046,070,937) 90,000,000 (6,193,867) (36,423,430) \$ 651,311,766 19,425,036 6,090,789 13,334,247 68,64% 12,135,680 6,057,173	(1,500)	(1,045) 8,090,319	\$ 148,312,518 (54,644,183) 8,090,319 (6,193,867) (36,423,430)	N/A N/A N/A N/A S3,164 204,536	17,211,468 - 2,727,273 - - - 19,938,741 N/A N/A N/A N/A N/A 20,651 204,536	\$ 50,000,000 (32,788,532) 2,727,273 - - \$ 19,938,741 N/A N/A N/A N/A N/A 404,068 204,536
	Less: Contributions Plus: Recallable Distributions Less: Reduction for No Self-Charged Management Fee to General Partner Less: Deemed Contribution Plus: Other Adjustment Ending Unfunded Commitment Portfolio Company Remuneration ("PCR") Information (Monitoring and Clost Total PCR Received by the Manager ("Total PCR")* PCR Received by the Manager, Allocable to Related Entities PCR Received by the Manager, Allocable to REP III* Percentage of Total PCR Allocable to REP III LPS Remaining PCR Offset Allocable to REP III LPS Remaining PCR Offset Allocable to REP III LPS Percentage of PCR Allocable to REP III LPS Remaining PCR Offset Allocable to REP III LPS Remaining PCR Received by the Manager only includes PCR received in relation to REP III Portfolio Companies held by REP III and Related Entities	(4,020,245) \$ 651,311,766 ng Fees): 2,139,672 385,257 1,754,414 81,99% 1,596,716 6,057,173	(2,801,608) 90,000,000 - - - S 651,311,766 3,638,949 977,473 2,661,476 73,14% 2,422,245 6,057,173	\$ 1,650,000,000 (1,046,070,937) 90,000,000 (6,193,867) (36,423,430) \$ 651,311,766 19,425,036 6,090,789 13,334,247 68,64% 12,135,680 6,057,173	(1,500)	(1,045) 8,090,319	\$ 148,312,518 (54,644,183) 8,090,319 (6,193,867) (36,423,430)	N/A N/A N/A N/A S3,164 204,536	17,211,468 - 2,727,273 - - - 19,938,741 N/A N/A N/A N/A N/A 20,651 204,536	\$ 50,000,000 (32,788,532) 2,727,273 - - \$ 19,938,741 N/A N/A N/A N/A N/A 404,068 204,536
	Less: Contributions Plus: Recallable Distributions Less: Reduction for No Self-Charged Management Fee to General Partner Less: Deemed Contribution Plus: Other Adjustment Ending Unfunded Commitment Portfolio Company Remuneration ("PCR") Information (Monitoring and Closi Total PCR Received by the Manager ("Total PCR")* PCR Received by the Manager, Allocable to Related Entities PCR Received by the Manager, Allocable to ReP III* Percentage of Total PCR Allocable to REP III LPs Remaining PCR Offiset Allocable to REP III LPs Remaining PCR Offiset Allocable to REP III LPs Remaining PCR Offiset Allocable to REP III LPs Percentage of PCR Allocable to REP III LPs Remaining PCR Offiset Allocable to REP III LPs Remaining PCR Offise	(4,020,245) \$ 651,311,766 ng Fees): 2,139,672 385,257 1,754,414 81,99% 1,596,716 6,057,173	(2,801,608) 90,000,000 - - - S 651,311,766 3,638,949 977,473 2,661,476 73,14% 2,422,245 6,057,173	\$ 1,650,000,000 (1,046,070,937) 90,000,000 (6,193,867) (36,423,430) \$ 651,311,766 19,425,036 6,090,789 13,334,247 68,64% 12,135,680 6,057,173	(1,500)	(1,045) 8,090,319	\$ 148,312,518 (54,644,183) 8,090,319 (6,193,867) (36,423,430)	N/A N/A N/A N/A S3,164 204,536	17,211,468 - 2,727,273 - - - 19,938,741 N/A N/A N/A N/A N/A 20,651 204,536	\$ 50,000,000 (32,788,532) 2,727,273 - - \$ 19,938,741 N/A N/A N/A N/A N/A 404,068 204,536
	Less: Contributions Plus: Recallable Distributions Less: Reduction for No Self-Charged Management Fee to General Partner Less: Deemed Contribution Plus: Other Adjustment Ending Unfunded Commitment Portfolio Company Remuneration ("PCR") Information (Monitoring and Clost Total PCR Received by the Manager ("Total PCR")* PCR Received by the Manager, Allocable to Related Entities PCR Received by the Manager, Allocable to REP III* Percentage of Total PCR Allocable to REP III LPs Remaining PCR Offset Allocable to REP III LPs Remaining PCR Offset Allocable to REP III LPs Remaining PCR Offset Allocable to REP III LPs Percentage of PCR Allocable to REP III LPs Remaining PCR Offset Allocable to REP III LPs Remaining PCR Offset Allocable to REP III LPs that was or will be Offset Against LP Management Fees *Total PCR Received by the Manager only includes PCR received in relation to REP III Portfolio Companies held by REP III and Related Entities **The use of REP III above indicates Ridgemont Equity Partners III, L.P. and Ridgemont Equity Partners Affiliates III, L.P.	(4,020,245) \$ 651,311,766 ng Fees): 2,139,672 385,257 1,754,414 81,99% 1,596,716 6,057,173	(2,801,608) 90,000,000 - - - S 651,311,766 3,638,949 977,473 2,661,476 73,14% 2,422,245 6,057,173	\$ 1,650,000,000 (1,046,070,937) 90,000,000 (6,193,867) (36,423,430) \$ 651,311,766 19,425,036 6,090,789 13,334,247 68,64% 12,135,680 6,057,173	(1,500)	(1,045) 8,090,319	\$ 148,312,518 (54,644,183) 8,090,319 (6,193,867) (36,423,430)	N/A N/A N/A N/A S3,164 204,536	17,211,468 - 2,727,273 - - - 19,938,741 N/A N/A N/A N/A N/A 20,651 204,536	\$ 50,000,000 (32,788,532) 2,727,273 - - \$ 19,938,741 N/A N/A N/A N/A N/A 404,068 204,536
	Less: Contributions Plus: Recallable Distributions Less: Reduction for No Self-Charged Management Fee to General Partner Less: Deemed Contribution Plus: Other Adjustment Ending Unfunded Commitment Portfolio Company Remuneration ("PCR") Information (Monitoring and Clost Total PCR Received by the Manager ("Total PCR")* PCR Received by the Manager, Allocable to Related Entities PCR Received by the Manager, Allocable to REP III* PCR Received by the Manager, Allocable to REP III PCR Received by the Manager, Allocable to REP III LPS Percentage of Total PCR Allocable to REP III LPS Remaining PCR Offset Allocable to REP III LPs Percentage of PCR Allocable to REP III LPs Percentage of PCR Allocable to REP III LPs that was or will be Offset Against LP Management Fees **Total PCR Received by the Manager only includes PCR received in relation to REP III Portfolio Companies held by REP III and Related Entities **The use of REP III above indicates Ridgemont Equity Partners III, L.P. and Ridgemont Equity Partners Affiliates III, L.P. Line of Credit Disclosures as of September 30, 2021	(4,020,245)	(2,801,608) 90,000,000 - - - S 651,311,766 3,638,949 977,473 2,661,476 73,14% 2,422,245 6,057,173	\$ 1,650,000,000 (1,046,070,937) 90,000,000 (6,193,867) (36,423,430) \$ 651,311,766 19,425,036 6,090,789 13,334,247 68,64% 12,135,680 6,057,173	(1,500)	(1,045) 8,090,319	\$ 148,312,518 (54,644,183) 8,090,319 (6,193,867) (36,423,430)	N/A N/A N/A N/A S3,164 204,536	17,211,468 - 2,727,273 - - - 19,938,741 N/A N/A N/A N/A N/A 20,651 204,536	\$ 50,000,000 (32,788,532) 2,727,273 - - \$ 19,938,741 N/A N/A N/A N/A N/A 404,068 204,536
	Less: Contributions Plus: Recallable Distributions Less: Reduction for No Self-Charged Management Fee to General Partner Less: Deemed Contribution Plus: Other Adjustment Ending Unfunded Commitment Portfolio Company Remuneration ("PCR") Information (Monitoring and Clos Total PCR Received by the Manager ("Total PCR")* PCR Received by the Manager, Allocable to Related Entities PCR Received by the Manager, Allocable to REP III * Percentage of Total PCR Allocable to REP III LPS Remaining PCR Offset Allocable to REP III LPS Remaining PCR Offset Allocable to REP III LPS Percentage of PCR Allocable to REP III LPs Percentage of PCR Allocable to REP III LPs Percentage of PCR Allocable to REP III LPs that was or will be Offset Against LP Management Fees **Total PCR Received by the Manager only includes PCR received in relation to REP III Portfolio Companies held by REP III and Related Entities **The use of REP III above indicates Ridgemont Equity Partners III, L.P. and Ridgemont Equity Partners Affiliates III, L.P. Line of Credit Disclosures as of September 30, 2021 Total Size of Facility Average Number of Davs Outstanding per Draw Down (Since Incention)	(4,020,245) \$ 651,311,766 ng Fees): 2,139,672 385,257 1,754,414 81,99% 1,596,716 6,057,173	(2,801,608) 90,000,000 - - - S 651,311,766 3,638,949 977,473 2,661,476 73,14% 2,422,245 6,057,173	\$ 1,650,000,000 (1,046,070,937) 90,000,000 (6,193,867) (36,423,430) \$ 651,311,766 19,425,036 6,090,789 13,334,247 68,64% 12,135,680 6,057,173	(1,500)	(1,045) 8,090,319	\$ 148,312,518 (54,644,183) 8,090,319 (6,193,867) (36,423,430)	N/A N/A N/A N/A S3,164 204,536	17,211,468 - 2,727,273 - - - 19,938,741 N/A N/A N/A N/A N/A 20,651 204,536	\$ 50,000,000 (32,788,532) 2,727,273 - - \$ 19,938,741 N/A N/A N/A N/A N/A 404,068 204,536
Corev Wilki	Less: Contributions Plus: Recallable Distributions Less: Reduction for No Self-Charged Management Fee to General Partner Less: Deemed Contribution Plus: Other Adjustment Ending Unfunded Commitment Portfolio Company Remuneration ("PCR") Information (Monitoring and Clost Total PCR Received by the Manager ("Total PCR")* PCR Received by the Manager, Allocable to Related Entities PCR Received by the Manager, Allocable to REP III* Percentage of Total PCR Allocable to REP III LPS Remaining PCR Offset Allocable to REP III LPS Remaining PCR Offset Allocable to REP III LPS Percentage of PCR Allocable to REP III LPS Percentage of PCR Allocable to REP III LPS that was or will be Offset Against LP Management Fees "Total PCR Received by the Manager only includes PCR received in relation to REP III Portfolio Companies held by REP III and Related Entities "The use of REP III above indicates Ridgemont Equity Partners III, L.P. and Ridgemont Equity Partners Affiliates III, L.P. Line of Credit Disclosures as of September 30, 2021 Total Size of Facility Average Number of Days Outstanding per Draw Down (Since Inception)	(4,020,245)	(2,801,608) 90,000,000 - - - S 651,311,766 3,638,949 977,473 2,661,476 73,14% 2,422,245 6,057,173	\$ 1,650,000,000 (1,046,070,937) 90,000,000 (6,193,867) (36,423,430) \$ 651,311,766 19,425,036 6,090,789 13,334,247 68,64% 12,135,680 6,057,173	\$ 59,141,357	(1,045) 8,090,319	\$ 148,312,518 (54,644,183) 8,090,319 (6,193,867) (36,423,430)	N/A N/A N/A N/A S3,164 204,536 100.00%	17,211,468 - 2,727,273 - - - 19,938,741 N/A N/A N/A N/A N/A 20,651 204,536	\$ 50,000,000 (32,788,532) 2,727,273 - - \$ 19,938,741 N/A N/A N/A N/A N/A 404,068 204,536
Corey Wilki	Less: Contributions Plus: Recallable Distributions Less: Reduction for No Self-Charged Management Fee to General Partner Less: Deemed Contribution Plus: Other Adjustment Ending Unfunded Commitment Portfolio Company Remuneration ("PCR") Information (Monitoring and Closi Total PCR Received by the Manager ("Total PCR")* PCR Received by the Manager, Allocable to Related Entities PCR Received by the Manager, Allocable to REP III PCR Received by the Manager, Allocable to REP III PCR Received by the Manager, Allocable to REP III PCR Received by the Manager, Allocable to REP III PCR Received by the Manager, Allocable to REP III PCR Received by the Manager, Allocable to REP III PCR Received Manager, Allocable to REP III LPS Percentage of PCR Allocable to REP III LPS Percentage of PCR Allocable to REP III LPs Percentage of PCR Allocable to REP III LPs that was or will be Offset Against LP Management Fees *Total PCR Received by the Manager only includes PCR received in relation to REP III Portfolio Companies held by REP III and Related Entities **The use of REP III above indicates Ridgemont Equity Partners III, L.P. and Ridgemont Equity Partners Affiliates III, L.P. Line of Credit Disclosures as of September 30, 2021 Total Size of Facility Average Number of Days Outstanding per Draw Down (Since Inception) Salance of Outstanding Borrowings, for the Period Ending September 30, 2021	(4,020,245)	(2,801,608) 90,000,000 - - - S 651,311,766 3,638,949 977,473 2,661,476 73,14% 2,422,245 6,057,173	\$ 1,650,000,000 (1,046,070,937) 90,000,000 (6,193,867) (36,423,430) \$ 651,311,766 19,425,036 6,090,789 13,334,247 68,64% 12,135,680 6,057,173	\$ 59,141,357	(1,045) 8,090,319	\$ 148,312,518 (54,644,183) 8,090,319 (6,193,867) (36,423,430)	S 19,938,741 \$ N/A N/A N/A N/A S3,164 204,536 100.00%	17,211,468 - 2,727,273 - - - 19,938,741 N/A N/A N/A N/A N/A 20,651 204,536	\$ 50,000,000 (32,788,532) 2,727,273 - - \$ 19,938,741 N/A N/A N/A N/A N/A 404,068 204,536
Corey Wilki 11/14/2021	Less: Contributions Plus: Recallable Distributions Less: Reduction for No Self-Charged Management Fee to General Partner Less: Deemed Contribution Plus: Other Adjustment Ending Unfunded Commitment Portfolio Company Remuneration ("PCR") Information (Monitoring and Clost Total PCR Received by the Manager ("Total PCR")* PCR Received by the Manager, Allocable to Related Entities PCR Received by the Manager, Allocable to REP III* Percentage of Total PCR Allocable to REP III LPS Remaining PCR Offset Allocable to REP III LPS Remaining PCR Offset Allocable to REP III LPS Percentage of PCR Allocable to REP III LPS Percentage of PCR Allocable to REP III LPS that was or will be Offset Against LP Management Fees "Total PCR Received by the Manager only includes PCR received in relation to REP III Portfolio Companies held by REP III and Related Entities "The use of REP III above indicates Ridgemont Equity Partners III, L.P. and Ridgemont Equity Partners Affiliates III, L.P. Line of Credit Disclosures as of September 30, 2021 Total Size of Facility Average Number of Days Outstanding per Draw Down (Since Inception)	(4,020,245) S 651,311,766 Ing Fees): 2,139,672 385,257 1,754,414 81,99% 1,596,716 6,057,173 100.00% 300,000,000 97	(2,801,608) 90,000,000 - - - S 651,311,766 3,638,949 977,473 2,661,476 73,14% 2,422,245 6,057,173	\$ 1,650,000,000 (1,046,070,937) 90,000,000 (6,193,867) (36,423,430) \$ 651,311,766 19,425,036 6,090,789 13,334,247 68,64% 12,135,680 6,057,173	\$ 59,141,357	(1,045) 8,090,319	\$ 148,312,518 (54,644,183) 8,090,319 (6,193,867) (36,423,430)	N/A N/A N/A N/A S3,164 204,536 100.00%	17,211,468 - 2,727,273 - - - 19,938,741 N/A N/A N/A N/A N/A 20,651 204,536	\$ 50,000,000 (32,788,532) 2,727,273 - - \$ 19,938,741 N/A N/A N/A N/A N/A 404,068 204,536